ASCO Abstracts 2020
ASCO Abstracts ASCO: Phase III QUAZAR AML-001 trial Abstract No : 7530 Abstract Type : Poster Discussion Session Indication : Acute Myeloid Leukemia Intervention : CC-486 Company : BMS Technology : Small molecule CC-486 is safe and well-tolerated as maintenance therapy in elderly patients ($75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial. ASCO: KEYNOTE-189 study Abstract No : 9582 Abstract Type : Poster Session Indication : Nonsquamous NSCLC Intervention : Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) Company : Merck Sharp & Dohme Corp. Technology : Monoclonal antibody Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC ASCO: Initial KarMMa results ...